Autoscriber Founders Koen Bonenkamp and Jacqueline Kazmaier

Autoscriber, a Dutch start-up developing AI-supported voice recognition software to capture and summarize healthcare professional-patient consultations, receives funding from LUMO Labs’ investment vehicle LUMO Fund II TTT AI. “We are thrilled to have found the perfect partner in LUMO Labs to support us both financially and strategically as we start to roll out Autoscriber and realize our vision towards enabling the future of healthcare,” said Jacqueline Kazmaier, co-founder and CEO.

Health professionals can access Autoscriber as a subscription-based software-as-a-service (SaaS) solution for large hospitals and practices, smaller practices, and general practitioners. LUMO Labs’ pre-seed funding will allow Autoscriber to go live in hospitals during the next 12 months.

The technology, which promises to streamline clinical interactions into a seamless experience for patients and caregivers, was developed in collaboration with the Clinical Artificial Intelligence and Research Lab (CAIRELab) at Leiden University Medical Center. “We are very excited to work so closely with the LUMC. Every design choice we make we validate with the physician in a clinical setting”, said Koen Bonenkamp, co-founder and CTO.

Subscribe to our Newsletter!

Your weekly innovation overview Every sunday the best articles of the week in your inbox.

    Autoscriber software records, transcribes, and extracts clinical concepts during consultations. It allows for automated summaries and integration in the patient’s Electronic Health Record that can be easily edited by the physician, providing real-time support for diagnostics and personalized care.

    Autoscriber’s value proposition is at the intersection of three crucial healthcare trends:

    • affordable and accessible healthcare for all
    • growing importance of structured/discrete data capture to support data-driven healthcare initiatives
    • increasing desire for understanding and self-determination among patients

    LUMO Labs is investing “because Autoscriber shows a strong entrepreneurial founding team with profound expertise, a proof-of-concept, and the promise to dramatically improve the lives of caregivers and patients”, said LUMO Labs founding partner Andy Lürling. “The problem Autoscriber is solving is universal: reducing time and money spent on repetitive, administrative tasks by physicians while increasing transparency, comprehensibility, and human interaction in deeply personal treatment situations. Their solution is dynamic and highly scalable because of the strong technological and human-centered set-up.”

    LUMO Labs’ founding partner Sven Bakkes noted the team is already well connected and supported by the academic/medical community they intend to serve, such as CAIRELab. CAIRELab’s mission is to improve healthcare with digital intelligence. “With Autoscriber, we found the right innovation partner in our ambition to bring a valuable AI solution into medical practice and perform scientific research for LUMC,” said Marjolein Elderhorst, manager VBHC & AI at CAIRELab. “Ultimately, the goal is to make Autoscriber available for the entire healthcare industry,” Elderhorst said.

    Autoscriber’s main partners to date are the Leiden University Medical Center and Google. “We believe Autoscriber’s potential going forward is massive, and we’re thrilled to be part of their next step,” Lürling said. “We look forward to working with Jacqueline and Koen and to supporting them to further scale and expand Autoscriber’s impact”, Bakkes added.

    Support us!

    Innovation Origins is an independent news platform that has an unconventional revenue model. We are sponsored by companies that support our mission: to spread the story of innovation. Read more.

    At Innovation Origins, you can always read our articles for free. We want to keep it that way. Have you enjoyed our articles so much that you want support our mission? Then use the button below:

    Doneer

    Personal Info

    About the author

    Author profile picture